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ABSTRACT 
 
Introduction: A major challenge has arisen regarding the treatment of infections caused by Gram-negative bacilli, 
particularly those with high level intrinsic resistance to many antibiotic classes and extreme ability to acquire 
resistance. Aim: The present study was conducted to assess the safety and efficacy of aerosolized polymyxin-B in 
comparison to intravenous polymyxin-B therapy for treatment of MDR GNB. Materials and methods: Study was 
performed over a period of 18 months. A Comparative two group randomized clinical study with 50 patients with 25 
patients in Group A and 25 patients in Group-B is undertaken to study the outcome of therapy, fever response to 
therapy and side effects. Results: Mean duration of ICU stay was 28.68±9.15 days in Group-A while it was 
31.64±9.16 days in Group-B. This was not statistically significant with p-value 0.258786. Pseudomonas aeruginosa 
is the most common organism isolated .In this study improvement, cure and failure rates were 44%, 44% and 12% 
respectively in Group-A(inhaled polymyxin b). while improvement,cure and failure rates were 40%,20% and 40%  
in Group-B(iv Polymyxin B) which was statistically significant. fever response to study was better in  Group-A 
(inhaled polymyxin B) which was statistically significant. Adverse events to polymyxin B Inhalation 
(bronchospasm) occurred in 16% of the patients in group-A , Nephotoxicity in 28% of patients in group –B.but  did 
not lead to suspension of treatment.  Conclusion: Inhaled polymyxin-B was useful in treatment of nosocomial 
pneumonia caused by MDR-GNB in mechanically ventilated patients. As the drug is given by inhalational route 
systemic side effects can be minimized 
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Introduction 
Emergence of nosocomial bacterial pathogens with 
acquired resistance to almost all available antimicrobial 
agents, namely ‘superbugs’, has severely threatened 
therapeutic choices in the last decade[1].A major 
challenge has arisen regarding the treatment of 
infections caused by Gram-negative bacilli, particularly 
those with high level intrinsic resistance to many 
antibiotic classes and extreme ability to acquire 
resistance, such as Pseudomonas aeruginosa and 
Acinetobacter baumannii [2]. No new antibiotic is 
there even in the drug development pipeline for MDR 
Gram-negative bacteria. The clinical and economic 
consequences of the emergence of multidrug-resistant 
Gram negative bacteria in the intensive care unit (ICU)  
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setting, combined with the high mortality rate among 
patients with nosocomial pneumonia, have stimulated a 
search for alternative therapeutic options to treat such 
infections. This therapeutic void has created a 
resurgence of interest in polymyxins[3].
 
Because of 
nephrotoxicity, neuromuscular blockade, neurotoxicity 
with systemic use of polymyxins, aerosolized therapy 
is used as an alternative method for treating MDR 
GNB [4, 5]Aerosolized therapy  in place of systemic 
treatment appears promising, but the current published 
data are too limited to allow determination of the 
incremental benefit of aerosolized treatment to 
systemic treatment. The present study was conducted 
to assess the safety and efficacy of aerosolized 
polymyxin B in comparison to intravenous polymyxin 
B therapy for treatment of MDR GNB. 
 
Materials and methods 
 
Study was conducted in the ICU of Osmania General 
Hospital, Hyderabad which is a tertiary care centre. 
Study was performed over a period of 18 months. A 
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Comparative two group randomized clinical study with 
50 patients with 25 patients in Group A and 25 patients 
in Group-B is undertaken to study the outcome of 
therapy, fever response to therapy and side effects. The 
study protocol was approved by ethical committee of 
the institution. Informed consent from the patient’s was 
taken. 
Inclusion Criteria: Cases of either sex aged between 
18 - 70 years, Patients on ventilator for >48 hours. 
Exclusion Criteria: Patients with pneumonia prior to 
ICU admission, ARDS, pulmonary edema, raised renal 
parameters 
Inclusion & exclusion criteria were choosen to prevent 
variables identified to be associated with mortality in 
mechanically ventilated patients.  
The patients were divided randomly into two groups: 
Group – A: Polymyxin - B  inhaled for   14 days 2 
mg/kg/day in  two divided doses in a solution of 5 mL 
of distilled water through a conventional nebulizer. 
Approximately 20 min before the  polymyxin B 
inhalation, an aerosolized beta2-agonist was 
administered. 
Group – B:    Polymyxin – B  i.v   for 14 days  2 
mg/kg/day in two divided  doses administered over one 
hour 
A total of 25 patients over one year period (August 
2011 through July 2012) with pneumonia caused by 
MDR-GNB were treated with nebulized Polymyxin – 
B. Compared with I.V Polymyxin –B in equal number 
of patients 
The following information was obtained for each 
patient. Basic investigation were done and also X – ray 
showing new or progressive  pulmonary infiltrates 
Fever  >  100.4 ⁰  F, Increased amount and purulence 
of tracheal secretions, Leucocytosis > 12,000 
cells/mm
3
 . 
If resistant to 4 or more of the following antimicrobial 
agents: An endotracheal aspirate was obtained 
immediately following clinical suspicion. 
Microbiological diagnosis of VAP was established by 
positive  cultures of bronchial secretions with isolation 
of an MDR gram-negative bacterium with a 
concentration of ≥104 CFU/ml . 
The response to treatment was assessed at the time of 
discharge from the ICU or at the end of antimicrobial 
therapy, especially if the patient remained hospitalized 
for a non VAP-related disease. 
The primary end point of the study was the clinical 
outcome of VAP. In patients with normal renal 
function, nephrotoxicity was defined as a serum 
creatinine value >2 mg/dL. Bronchospasm during 
inhaled polymyxin, defined as the increase of 
respiratory frequency  
associated with wheezing, was evaluated. 
The therapeutic response was evaluated by one of the 
following criteria: 
Improvement. Defined as the reduction and 
improvement of the appearance of tracheal secretions, 
reduction or disappearance of chest X-ray alterations, 
normalization of leukocyte count, patient becoming 
afebrile and improvement of the mechanical ventilation 
parameters (FIO2 and positive end expiratory pressure 
[PEEP]). 
Cure. Criteria for improvement plus disappearance of 
fever, return of spontaneous ventilation, and discharge 
from the ICU or the hospital. 
Failure All the situations not classified as 
improvement or cure.( persistence or worsening of 
presenting symptoms and/or signs of infection during 
polymyxin administration) 
.Descriptive statistical has been carried out in the 
present study. Results on continuous measurements are 
presented on Mean ± SD (Min-Max) and results on 
categorical measurements are presented in Number 
(%).Statistical analysis was done by applying Chi-
square test and P < 0.05 is significant ,P < 0.001 is 
highly significant 
 
Results 
 
It is a Comparative two group randomized clinical 
study with 50 patients with 25 patients in Group A and 
25 patients in Group-B is undertaken to study the 
outcome of therapy , fever response to therapy and side 
effects.  Study was done for period of 18 months .Out 
of 25 patients 17 are male and 8 are female patients. 
 
Table1: Age distribution of patients studied 
 
Age in yrs GROUP-A % GROUP-B % 
18-30 7 28 6 24 
31-50 12 48 13 52 
51-70 6 24 6 24 
Mean age in years (±SD) 41.4±13.10      41.36±13.06  
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The T-value is 0. The P-Value is 1. The result is not significant at p < 0.05. The patients who took part in this study 
were in the age group of 18 to 70 years. On statistical comparison the two groups were comparable. 
 
 
 
 
 
Figure 1: Duration of ICU Stay 
 
The T-value is 1.142809. The P-Value is 0.258786. The result is not significant at p < 0.05. 
 
Table 2:  Microorganism Isolated 
 
Microorganism GROUP-A GROUP-B 
Pseudomonas aeruginosa 15 60% 14 56% 
Acinetobacter baumannii 5 20% 4 16% 
Klebsiella pneumonia 5 20% 7 28% 
Pseudomonas aeruginosa is the most common organism isolated. 
The chi-square statistic is 0.4789. The P-Value is 0.78705. The result is not significant at p < 0.05. 
 
t- 
Value: 4.217922, p-value:0.000264.The result is significant at p value<0.05. 
 
Figure 2: Fever response to therapy 
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Figure 3: Outcome of therapy 
 
The chi-square statistic is 6.0668. The P-Value is 0.04815. The result is significant at p < 0.05 
 
Table 3: Side effects of patients in two groups studied 
 
Side Effect Group-A Group-B 
Bronchospasm 4(16%) 0 
Nephrotoxicity 0 7(28%) 
 
Discussion 
 
Inhaled antibiotics have been used based on the 
rationale that the drug would concentrate at the 
infection site minimizing toxicity of systemic 
administration, and this strategy has gained strength. 
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Gram-negative bacilli and especially P. aeruginosa are 
among the important causes of nosocomial infections 
worldwide. In this setting, treatment with inhaled 
polymyxin B may prove to be an interesting alternative 
because the systemic use of polymyxins seems to yield 
poor results. There are no other studies which compare 
inhaled polymyxin B alone with IV polymyxin B 
alone. The present study was performed to evaluate the 
effectiveness and safety of  inhaled polymyxin Bin 
MDR Pneumonia patients. In this study the inhalational 
and intravenous dosing regimen was selected based on 
previous animal studies and ICU practices in this 
institution. In this study Group-A received 2mg/kg 
(20000U/kg) polymyxin B via  inhalation and Group-B 
received  2 mg/kg polymyxin B intravenously. These 
doses were given in two divided doses as preferential 
accumulation of polymyxin B in the kidneys  is a 
nonpassive process and q12h dosing was less 
nephrotoxic than q6h dosing[6].The baseline 
information was obtained for each patient. Defined as 
the reduction and improvement of the appearance of 
tracheal secretions, reduction or disappearance of chest 
X-ray alterations, normalization of leukocyte count, 
patient becoming a febrile and improvement of the  
mechanical ventilation parameters (FIO2 and positive 
end expiratory pressure [PEEP]). Criteria for 
improvement plus disappearance of fever, return of 
spontaneous ventilation, and discharge from the ICU or 
the hospital. All the situations not classified as 
improvement or cure. (persistence or worsening of 
presenting symptoms and/or signs of infection during 
polymyxin administration) In this study improvement, 
cure and failure rates were 44%, 44% and 12% 
respectively in Group-A(inhaled polymyxin b). While 
improvement, cure and failure rates were 40%, 20% 
and 40%  in Group-B(iv Polymyxin B) which was 
statistically significant. Graziella H. Pereiraa et al study 
showed that the outcome of treatment with inhaled 
polymyxin B was cure in 53%, improvement in 42%  
and failure in 5%.In our study fever response to study 
was better in  Group-A (inhaled polymyxin B) which 
was statistically significant. There are no studies which 
compared this factor. In our study adverse events to 
polymyxin B Inhalation (bronchospasm) occurred in 
16% of the patients in group-A but did not lead to 
suspension of treatment. Pereiraa et al [7] in their 
study showed that adverse events during polymyxin B 
inhalation occurred in 21%. Nephrotoxicity occurred in 
28% of Group-B patients while there was no 
nephrotoxicity in Group-A patients. Neurotoxicity, 
while difficult to assess in severely ill ICU patients, 
appeared minimal. In the lCU setting, sepsis, 
hypotension and the use of other nephrotoxic drugs 
contribute to impairment of renal function. Our study 
was not able to exclude the confounding impact of 
these variables because of our reliance on sometimes 
incomplete medical records and the complex nature of 
treating patients in ICU. Mean duration of ICU stay 
was 28.68±9.15 days in Group-A while it was 
31.64±9.16 days in Group-B. This was not statistically 
significant with p-value 0.258786.Kofteridis et al[8]  in 
their study also showed that ICU stay in two groups 
was not statistically significant. 
In a recent clinical study on polymyxin B[6], 60 
patients with nosocomial infections, mostly due 
to A. baumannii, were investigated. The majority of 
the patients were mechanically ventilated and had 
pulmonary infections. The iv polymyxin B dose was 
adjusted according to the estimated creatinine 
clearance: 20–50 mL/min, 75% of the total daily dose 
of 2.5 mg/kg; <20 mL/min, 33% of the total daily dose. 
The overall mortality of these patients was 20%. 
Bacteria were cleared in 88% of the patients; however, 
susceptibility testing revealed that the bacteria 
persisting in other patients remained susceptible to 
polymyxin B. A major drawback in both clinical 
efficacy and microbiological endpoint analyses is that 
up to 90% of patients received combination therapy 
with another agent active against  
P. aeruginosa and A. baumannii[9]In another study, 
only patients who received combination therapy were 
included.
 
Twenty-nine treatments from 25 patients 
were analysed. Ninety-two per cent of the patients were 
from intensive care units and 88% were mechanically 
ventilated. All patients had respiratory tract infections 
caused by A. baumannii (55%), P. aeruginosa (41%) 
and Alcaligenesxylosoxidans (3%).Onlyseven A. bau
mannii and five P. aeruginosa isolates were resistant 
to all available antibiotics except polymyxin B. Since 
all patients were treated with another antibiotic, 
efficacy analysis of polymyxin B was 
compromised.[9].the overall discharge mortality was 
48%. Follow-up cultures were available in 22 cases, of 
which 9 achieved microbiological clearance but were 
associated with a longer duration of therapy. 
Resistance to polymyxin B was not observed during 
the therapy [9].Holloway et al[10] recently published 
their experience with the treatment of 37 patients with 
infections due to polymyxin-only-susceptible A. 
baumannii, of whom 33 received polymyxin B 
therapy. Monotherapy with polymyxin B was used in 
27 patients. Most infections were ventilator-associated 
pneumonia. Nine (27%) patients died after treatment 
with polymyxin B. Microbiological cure was achieved 
in 17 (81%) of 21 patients evaluated for this outcome 
[11].In our recent study on the treatment of 13 patients 
with iv polymyxin B against infections caused by 
MDR metallo–β-lactamase-
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producing P.aeruginosa,65 8 patients had pneumonia, 
of whom 4 were ventilator-associated. Overall in-
hospital mortality was 54%.65 Of six patients with 
ventilator-associated pneumonia treated with 
polymyxin B, four (67%) died within 30 days after 
initial treatment with polymyxin B [12].Mortality rates 
(VAP mortality and all cause mortality rates) were not 
compared in our study because we excluded patients 
with raised renal parameters, ARDS and pulmonary 
edema. This would have been confounding factor in 
evaluation of mortality rates. Duration of mechanical 
ventilation was also not evaluated as the patients were 
being ventilated mechanically for reasons other than 
MDR VAP. Though there are limitations in our study 
outcome of inhaled polymyxin B therapy is significant. 
The response was good and might be explained by the 
possible high concentration of the inhaled drug in the 
pulmonary compartment. In our study the isolates were 
not tested for polymyxin B resistance because 
microdilution was not available and disk diffusion is 
not a reliable method. This could have acted as a 
confounding factor in failure cases. The 
pharmacokinetic properties and dosing strategies of 
aerosolized polymyxin are not well defined. Whether 
the various forms of polymyxin used for inhalation 
therapy or the different types of nebulizing systems 
influence the effectiveness and safety of colistin 
remains to be determined [13-16].Further 
pharmacokinetic-pharmacodynamic studies in which 
serum concentrations achieved by varying doses of 
polymyxin are compared to the MIC of the infecting 
organisms are required so that the optimal dose of 
polymyxin can be determined. This is important not 
only for optimal effectiveness of the drug but also to 
prevent polymyxin resistance. 
 
Conclusions  
 
Aerosolized administration of Polymyxin B is a 
promising therapy for management of patients with 
pneumonia due to multi drug resistant Gram-negative 
bacteria. Aerosolized polymyxin B was safe in this 
group of patients. Inhaled Polymyxin-B deposits the 
drug at the site of infection and facilitates better 
antimicrobial action.  In summary, despite the 
limitations of this study, we considered that inhaled 
polymyxin-B was useful in treatment of nosocomial 
pneumonia caused by MDR-GNB in mechanically 
ventilated patients. As the drug is given by inhalational 
route systemic side effects can be minimized. The 
results of this study should lead to randomized 
controlled studies to establish the role of this form of 
treatment. 
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